<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026749</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300007862</org_study_id>
    <nct_id>NCT05026749</nct_id>
  </id_info>
  <brief_title>Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children</brief_title>
  <official_title>Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM)&#xD;
      during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be&#xD;
      beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will be a randomized, double-blinded, placebo-controlled Phase III trial&#xD;
      to examine the efficacy of AZM therapy relative to placebo in reducing RSV-related morbidity.&#xD;
      Patients will be recruited during acute hospitalization and admission to the ICU at 5&#xD;
      pediatric hospitals. The target population selected is pediatric patients with severe RSV&#xD;
      lung disease as defined by need for ICU management and intensive respiratory support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of hospitalization in days for enrolled subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygenation</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of oxygenation in days for enrolled subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of ICU stay in days for enrolled subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AZM 20mg/kg Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZM Group</intervention_name>
    <description>AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.</description>
    <arm_group_label>AZM 20mg/kg Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Admission to the pediatric ICU with a confirmed diagnosis of RSV infection. RSV&#xD;
             infection is based on a positive nasal swab for RSV fluorescent antibody or via&#xD;
             multiplex assay or culture;&#xD;
&#xD;
          -  Requiring intensive respiratory support defined as either mechanical ventilation or&#xD;
             NIV (BiPAP or CPAP) or HFNC (at &gt;1 L/kg/min of flow, with a minimum of 5L/min flow for&#xD;
             children &lt;5 kg);&#xD;
&#xD;
          -  Enrollment into the study within 48 hours of ICU admission and placement on intensive&#xD;
             respiratory support;&#xD;
&#xD;
          -  Age: Neonates-2 years. For those less than 1 week of age, they must have been&#xD;
             discharged home from the hospital after their birth.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  AZM use within 7 days of ICU admission;&#xD;
&#xD;
          -  Contraindication to AZM use including known hypersensitivity to AZM, erythromycin, any&#xD;
             macrolide, or ketolide drug, patients with significant hepatic impairment (direct&#xD;
             bilirubin &gt;1.5 mg/dL);&#xD;
&#xD;
          -  Patients with known cardiac disease, cardiac arrhythmia or with electrocardiogram QT&#xD;
             interval corrected for heart rate (QTc) â‰¥ 450 milisecond (ms);&#xD;
&#xD;
          -  Intensive respiratory support greater than 48 hours prior to ICU admission;&#xD;
&#xD;
          -  Chronic ventilation or supplemental oxygen need at home;&#xD;
&#xD;
          -  Immunosuppressive conditions such as those post heart or hematopoietic stem cell&#xD;
             transplant or receiving chemotherapy and chronic steroids;&#xD;
&#xD;
          -  History of pyloric stenosis;&#xD;
&#xD;
          -  AZM is deemed necessary for clinical treatment (for instance, if patient has&#xD;
             pertussis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Kong, MD</last_name>
    <phone>205-638-9387</phone>
    <email>mkong@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Kong, MD</last_name>
      <phone>205-638-9387</phone>
      <email>mkong@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Michele Kong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matt Zinter, MD</last_name>
      <email>Matt.Zinter@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8064</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Vince Faustino, MD</last_name>
      <email>vince.faustino@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Bell, MD</last_name>
      <email>mbell@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Michael Bell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bria Coates, MD</last_name>
      <email>b-coates@northwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michele Kong</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>RSV</keyword>
  <keyword>AZM</keyword>
  <keyword>ICU</keyword>
  <keyword>Respiratory Support</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To be determined.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

